Company news
InMed Pharmaceuticals Inc. news in 2021
InMed Pharmaceuticals Inc.'s news releases, calls and decks from 2021, newest first.
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma
December 19, 2021
InMed Announces Results of 2021 Annual General Meeting
December 16, 2021
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update
November 9, 2021
InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid
November 2, 2021
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
October 12, 2021
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
September 29, 2021
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update
September 23, 2021
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
September 12, 2021
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
June 28, 2021
InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules
June 28, 2021
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production
June 16, 2021
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results
May 12, 2021
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
April 27, 2021
InMed Pharmaceuticals Announces Voluntary Delisting from TSX
April 26, 2021
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
April 25, 2021
InMed Announces Closing of US$4.5 Million Private Placement
February 15, 2021
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
February 10, 2021
InMed Announces US$4.5 Million Private Placement
February 4, 2021
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
January 7, 2021
Calls in 2021
Decks in 2021
- Investor Presentation (April 2021)
Investor deck · 22 slides · Apr 28, 2021
- Investor Presentation (January 2021)
Investor deck · 32 slides · Jan 11, 2021